The Lancet Oncology<\/a>\u2019 en el que hi han participat 16 hospitals d\u2019arreu del continent europeu i que ha comptat amb la col\u00b7laboraci\u00f3 de l\u2019Institut Catal\u00e0 d\u2019Oncologia (ICO), l\u2019Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) i l\u2019Institut Valenci\u00e0 d\u2019Oncologia (IVO).<\/p>\nEn aquest estudi s\u2019han analitzat 1.328 pacients amb un tumor inicial de c\u00e0ncer de mama que, despr\u00e9s d\u2019una cirurgia conservadora de mama, han estat tractades aleat\u00f2riament el 50% amb irradiaci\u00f3 complerta de tota la mama (radioter\u00e0pia convencional) i l\u2019altra meitat amb braquiter\u00e0pia amb tubs pl\u00e0stics, irradiant nom\u00e9s el llit quir\u00fargic (al voltant d’on estava el tumor). Despr\u00e9s d\u2019un seguiment de 10 anys, s\u2019han complert els objectius inicials de l\u2019estudi: demostrar que es pot mantenir el control local i minimitzar aix\u00ed els efectes secundaris.<\/p>\n
\nTractaments m\u00e9s senzills i amb menys efectes secundaris<\/h3>\n
<\/p>\n
La principal conclusi\u00f3 \u00e9s que el tractament amb braquiter\u00e0pia durant nom\u00e9s 4-5 dies \u00e9s m\u00e9s r\u00e0pid davant les 30 sessions que es realitzen amb la radioter\u00e0pia externa i que duren 6 setmanes . Aix\u00f2 ja \u00e9s un benefici per a la pacient per\u00f2 no \u00e9s l\u2019\u00fanic ja que la braquiter\u00e0pia t\u00e9 menys efectes secundaris en la pell, la resta del teixit de la mama no es veu afectat i el pulm\u00f3 i el cor reben menys irradiaci\u00f3. Aquest fet minimitza les mol\u00e8sties per a les pacients i reverteix en el seu benestar, reduint el risc de complicacions a llarg termini.<\/p>\n
Per a la cap cl\u00ednic de la Unitat de Braquiter\u00e0pia de l\u2019ICO a l\u2019Hospitalet i investigadora de l\u2019IDIBELL, Cristina Gutierrez<\/strong>, \u201caquest estudi \u00e9s important perqu\u00e8 es demostra que tant la radioter\u00e0pia externa com la <\/em>braquiter\u00e0pia<\/em> s\u00f3n segures i eficaces, ja que ambd\u00f3s tractaments s\u00f3n equivalents a nivell de control local, per\u00f2, a m\u00e9s, les pacients tractades amb <\/em>braquiter\u00e0pia<\/em> tenen menys efectes secundaris\u201d<\/em> i afegeix \u201caquest estudi contribueix a donar a con\u00e8ixer la <\/em>braquiter\u00e0pia<\/em> en c\u00e0ncer de mama\u201d<\/em>.<\/p>\nPer la seva banda el cap del Servei d\u2019Oncologia Radioter\u00e0pica de l\u2019IVO, Jos\u00e9 Luis Guinot<\/strong>, destaca que \u201caquest \u00e9s el primer estudi a nivell mundial que ha demostrat que la irradiaci\u00f3 parcial de la mama (en lloc de radiar la mama sencera) \u00e9s el tractament d\u2019elecci\u00f3 per a pacients operades amb tumors de baix risc. Amb deu anys de seguiment es confirmen els resultats inicials, consolidant aquest canvi d’enfocament que beneficia milers de pacients amb el tipus de c\u00e0ncer m\u00e9s freq\u00fcent en dones<\/em>\u201d.<\/p>\n <\/p>\n
<\/p>\n
L\u2019Institut d’Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l’Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l’Institut Catal\u00e0 de la Salut, l’Institut Catal\u00e0 d’Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\nL\u2019IDIBELL \u00e9s membre del Campus d’Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L’any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"Aix\u00ed ho demostren els resultats d\u2019un estudi internacional que ha comptat amb la participaci\u00f3 de l\u2019Institut Catal\u00e0 d\u2019Oncologia (ICO), l\u2019Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) i l\u2019Institut Valenci\u00e0 d\u2019Oncologia (IVO) i en el que es fa una comparativa entre les dues t\u00e8cniques. <\/p>\n","protected":false},"author":8,"featured_media":23145,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[332,447,372],"tags":[],"class_list":["post-23144","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer","category-p-de-mecanismes-molelculars-i-terapia-experimental-en-oncologia-oncobell","category-radiobiologia-i-cancer"],"publishpress_future_action":{"enabled":false,"date":"2025-01-25 07:55:13","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/23144","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=23144"}],"version-history":[{"count":1,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/23144\/revisions"}],"predecessor-version":[{"id":23146,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/23144\/revisions\/23146"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/23145"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=23144"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=23144"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=23144"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}